Overview Fundamentals API Earnings EOD API Sample Code Pricing

Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF PINK) stock market data APIs

$0.295 0(0%) as of July 19, 2024
Price chart is built with Anychart

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company's drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor. In addition, the company is involved in the development of JAB-2485, an Aurora Kinase A inhibitor, under Phase I study indicated for the treatment of solid tumors; JAB-24114, a glutamine-utilizing enzyme inhibitor under IND study indicated for the treatment of solid tumors; and JAB-30355, an orally bioavailable small molecule activator under IND study for the treatment of patients with locally advanced or metastatic solid tumors. It has a license and collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.

Jacobio Pharmaceuticals Group Co. Ltd. Financial Data Overview

233 M
789 M
63 520 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'JBPHF',
Type: 'Common Stock',
Name: 'Jacobio Pharmaceuticals Group Co. Ltd.',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG016PJFDQ3',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,

Jacobio Pharmaceuticals Group Co. Ltd. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 63 520 K
  • EBITDA -401 124 000
  • Earnings Per Share -0.06
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Jacobio Pharmaceuticals Group Co. Ltd. Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Jacobio Pharmaceuticals Group Co. Ltd. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?